Free shipping on all orders over $ 500

Dalpiciclib

Cat. No. M10930
Dalpiciclib Structure
Synonym:

SHR-6390

Size Price Availability Quantity
5mg USD 450  USD450 In stock
10mg USD 700  USD700 In stock
25mg USD 1400  USD1400 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Dalpiciclib (SHR-6390) is a highly selective, oral bioavailable inhibitor of CDK4/6 that is used against CDK4 (IC50=12.4 nM) and CDK6 (IC50=9.9 nM) is equivalent. SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb protein and inducing G1 cell cycle blocking.

Chemical Information
Molecular Weight 446.54
Formula C25H30N6O2
CAS Number 1637781-04-4
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] M Saeed Sheikh, et al. Mol Cell Pharmacol. The emerging CDK4/6 inhibitor for breast cancer treatment

[2] Binghe Xu, et al. Nat Med. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

[3] No authors listed. Oncologist. Dalpiciclib Extends Progression-Free Survival in HR+/HER2- Advanced Breast Cancer

[4] Pin Zhang, et al. Biomark Res. A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer

Related CDK Products
PF-07224826

PF-07224826 is a CDK2/4/6 inhibitor.

INCB123667

INCB123667 is a CDK2 inhibitor.

Senexin B

Senexin B is a potent, orally active CDK8/19 inhibitor with Kd values of 140 nM and 80 nM for CDK8 and CDK19, respectively.

Q901

Q901 is a CDK7 inhibitor for tumor-related studies.

NUV-422

NUV-422 is a CDK2/4/6 inhibitor that can be used in studies related to malignant gliomas.

  Catalog
Abmole Inhibitor Catalog




Keywords: Dalpiciclib, SHR-6390 supplier, CDK, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.